Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
The research program of Michael P. Fautsch, PhD focuses on the development and treatment of glaucoma, an eye disease that affects nearly 60 million people and is the leading cause of irreversible blindness worldwide. Elevated intraocular pressure is the primary risk factor for the disease and it is with this purpose that Dr. Fautsch has devoted his research efforts to understanding the physiology of intraocular pressure regulation. Toward this understanding, his laboratory team is identifying new therapeutic targets and developing novel therapeutics to regulate pressure and preserve the function of the optic nerve, the ultimate site of eye damage leading to vision loss in glaucoma.
Elevated intraocular pressure is the primary risk factor responsible for optic nerve damage and loss of vision in glaucoma. Dr. Fautsch studies are geared towards identifying and characterizing new treatment options that will reduce elevated intraocular pressure and protect the optic nerve from damage in patients with glaucoma. Development of such drugs would improve treatment and further slow disease progression.
Learn about clinical trials that address specific scientific questions about human health and disease.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Review my research fingerprint, network, grants, projects, publications, Scopus profile, and Altmetrics scores and badges.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.